ACIU AC Immune
- 4.260
- -0.470-9.94%
AC Immune News
AC Immune SA (NASDAQ:ACIU) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
AC Immune SA (NASDAQ:ACIU) shareholders would be excited to see that the share price has had a great month, posting a 34% gain and recovering from prior weakness. The annual gain comes to 113% foll
Here's Why Shareholders May Want To Be Cautious With Increasing AC Immune SA's (NASDAQ:ACIU) CEO Pay Packet
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 250 points on Friday.Shares of RH (NYSE:RH) fell sharply in today's pre-market trading after the company reported mixed
BTIG Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $8
BTIG analyst Thomas Shrader maintains $AC Immune(ACIU.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 37.8% and a total avera
AC Immune SA (NASDAQ:ACIU): Are Analysts Optimistic?
The era of 5 million dementia patients has arrived, promising stocks and overall verification of social issues. <Stock Top Feature>
The second meeting of the conference for promoting dementia policies was held on May 8th, and it was estimated that the number of dementia patients would reach 5.231 million in 2030 (4.432 million in 2022). The "Basic Law on Dementia" was enacted in January of this year to realize a society in which people with dementia can live together, and discussions are underway to formulate a basic plan. However, to overcome the era of 5 million dementia patients, it is essential to utilize both policies and treatments, as well as technology. Therefore, this time, we focus on related stocks that confront social issues.
Loss-Making AC Immune SA (NASDAQ:ACIU) Expected To Breakeven In The Medium-Term
With the business potentially at an important milestone, we thought we'd take a closer look at AC Immune SA's (NASDAQ:ACIU) future prospects. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results.SentinelOne reported quarterly losses of 23 cents per share, which
Express News | AC Immune Shares Are Trading Higher After BTIG Initiated Coverage on the Stock With a Buy Rating and $8 Price Target
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday.Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and u
BTIG Starts AC Immune With Buy Rating, $8 Price Target
BTIG Starts AC Immune With Buy Rating, $8 Price Target.
AC Immune Initiated at Buy by BTIG
AC Immune Initiated at Buy by BTIG
AC Immune Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 91.85% BTIG → $8 Initiates Coverage On → Buy 03/15/2024 283.69% HC Wainwright & Co. → $16 Reite
Express News | AC Immune SA : Btig Initiates Coverage With Buy Rating and $8 Price Target
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
PDF Version 131.6 KB AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage
E.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday.Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply during Thursday's session after the company reported better
AC Immune SA: Progress and Promise in Neurodegenerative Disease
Individual Investors Own 24% of AC Immune SA (NASDAQ:ACIU) Shares but Private Equity Firms Control 30% of the Company
AC Immune | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | AC Immune SA : Jefferies Raises Target Price to $8 From $6.5
Analysis
Price Target
No Data
